Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
Frontiers in Oncology · 07.02.2025 · 14
DOI: 10.3389/fonc.2024.1492203 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 07.02.2025. Verfasst von Xiang Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer is a major health challenge for women worldwide, and human epidermal growth factor receptor 2 (HER-2)-positive breast cancers have a relatively high incidence and are highly aggressive. Targeted therapeutic agents, represented by trastuzumab, have been effective in improving the survival rate of HER-2-positive breast cancer patients. However, in clinical applications, this type of targeted drugs exhibits varying degrees of cardiotoxicity, and the mechanism of their cardiotoxicity is currently unclear. In this paper, we classify them into three categories: monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs), and antibody-drug conjugate (ADCs). We list the evidence of cardiotoxicity for various drugs based on current clinical trials and summarize their corresponding epidemiological profiles. We also discuss the regulation of cardiotoxicity from three perspectives: clinical biomarkers of cardiotoxicity, permissive cardiotoxicity, and the current status of cardiotoxicity regulation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Breast Surgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Hospital Administration Office, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zitieren
APA
Zhang, X., Yin, Y., Yu, Q., Chen, X., & Cheng, Y. (2025). Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1492203
Vancouver
Zhang X, Yin Y, Yu Q, Chen X, Cheng Y. Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs. Frontiers in Oncology. 2025;14. doi:10.3389/fonc.2024.1492203
BibTeX
@article{Zhang2025,
author = {Zhang, Xiang and Yin, Yulian and Yu, Qiuting and Chen, Xinlin and Cheng, Yiqin},
title = {Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs},
journal = {Frontiers in Oncology},
year = {2025},
volume = {14},
doi = {10.3389/fonc.2024.1492203}
}
EUVIMED